Piper Sandler analyst Edward Tenthoff downgraded Rapt Therapeutics (RAPT) to Neutral from Overweight with a price target of $2, down from $8, after the company announced it is terminating development of zelnecirnon following recent FDA feedback on resolution of the outstanding clinical hold due to one patient with severe liver injury in the AD study. Rapt continues to develop next generation preclinical CCR4 inhibitors and is continuing to seek a partner for tivumecirnon for NSCLC, the firm noted.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT: